Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,990 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer.
Santa-Maria CA, Kato T, Park JH, Kiyotani K, Rademaker A, Shah AN, Gross L, Blanco LZ, Jain S, Flaum L, Tellez C, Stein R, Uthe R, Gradishar WJ, Cristofanilli M, Nakamura Y, Giles FJ. Santa-Maria CA, et al. Among authors: jain s. Oncotarget. 2018 Apr 10;9(27):18985-18996. doi: 10.18632/oncotarget.24867. eCollection 2018 Apr 10. Oncotarget. 2018. PMID: 29721177 Free PMC article.
A pilot study of cabergoline for the treatment of metastatic breast cancer.
Costa R, Santa-Maria CA, Scholtens DM, Jain S, Flaum L, Gradishar WJ, Clevenger CV, Kaklamani VG. Costa R, et al. Among authors: jain s. Breast Cancer Res Treat. 2017 Oct;165(3):585-592. doi: 10.1007/s10549-017-4370-x. Epub 2017 Jul 3. Breast Cancer Res Treat. 2017. PMID: 28674764 Clinical Trial.
Breast cancer and immunology: biomarker and therapeutic developments.
Santa-Maria CA, Park SJ, Jain S, Gradishar WJ. Santa-Maria CA, et al. Among authors: jain s. Expert Rev Anticancer Ther. 2015;15(10):1215-22. doi: 10.1586/14737140.2015.1086270. Epub 2015 Sep 10. Expert Rev Anticancer Ther. 2015. PMID: 26358181 Review.
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer.
Shah AN, Flaum L, Helenowski I, Santa-Maria CA, Jain S, Rademaker A, Nelson V, Tsarwhas D, Cristofanilli M, Gradishar W. Shah AN, et al. Among authors: jain s. J Immunother Cancer. 2020 Feb;8(1):e000173. doi: 10.1136/jitc-2019-000173. J Immunother Cancer. 2020. PMID: 32060053 Free PMC article. Clinical Trial.
10,990 results
You have reached the last available page of results. Please see the User Guide for more information.